Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

AN ATTEMPT TO HALT THE EVER-INCREASING PREVALENCE OF MORBIDITIES RESULTING FROM EXCESS DIETARY SODIUM INTAKE. The Lebanese Experience.

Almedawar MM, Isma'Eel HA, Nasreddine L, Olabi A, Badr KF, Arnaout MS.

J Med Liban. 2016 Aug;64(2):63-64. No abstract available.

PMID:
30452141
2.

Effect of salt intake on beat-to-beat blood pressure nonlinear dynamics and entropy in salt-sensitive versus salt-protected rats.

Fares SA, Habib JR, Engoren MC, Badr KF, Habib RH.

Physiol Rep. 2016 Jun;4(11). pii: e12823. doi: 10.14814/phy2.12823.

3.

The long-term impact of team-based learning on medical students' team performance scores and on their peer evaluation scores.

Zgheib NK, Dimassi Z, Bou Akl I, Badr KF, Sabra R.

Med Teach. 2016 Oct;38(10):1017-1024. Epub 2016 Mar 23.

PMID:
27008548
4.

Crowd-funded micro-grants for genomics and "big data": an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropy.

Ă–zdemir V, Badr KF, Dove ES, Endrenyi L, Geraci CJ, Hotez PJ, Milius D, Neves-Pereira M, Pang T, Rotimi CN, Sabra R, Sarkissian CN, Srivastava S, Tims H, Zgheib NK, Kickbusch I.

OMICS. 2013 Apr;17(4):161-72. doi: 10.1089/omi.2013.0034.

5.

Regionalizing healthcare: a vision for transforming Lebanon into a regional academic hub.

Badr KF, Akl EA.

BMC Health Serv Res. 2010 Jun 16;10:167. doi: 10.1186/1472-6963-10-167.

6.

A 5-year survey of biopsy proven kidney diseases in Lebanon: significant variation in prevalence of primary glomerular diseases by age, population structure and consanguinity.

Karnib HH, Gharavi AG, Aftimos G, Mahfoud Z, Saad R, Gemayel E, Masri B, Assaad S, Badr KF, Ziyadeh FN.

Nephrol Dial Transplant. 2010 Dec;25(12):3962-9. doi: 10.1093/ndt/gfq302. Epub 2010 Jun 4.

7.

Physician assessment of stroke risk in hypertensive patients in the Middle East and Africa: results of the action survey.

Badr KF, Boudia KM, Alami M, Khoja WA, Belhani AB, Nawar M, Ragy H, Ishaq M, Baron JM, Hammoudeh AJ, De Mar Youssef SS, Nakhle RM, Chalfoun AG; Assessing and Reducing the Risk of Stroke in Hypertension Survey Group.

Ethn Dis. 2007 Spring;17(2):274-9.

PMID:
17682358
8.

Modulation of COX-2 expression by statins in human monocytic cells.

Habib A, Shamseddeen I, Nasrallah MS, Antoun TA, Nemer G, Bertoglio J, Badreddine R, Badr KF.

FASEB J. 2007 Jun;21(8):1665-74. Epub 2007 Feb 22.

PMID:
17317725
9.

Measuring filtration function in clinical practice.

Fawaz A, Badr KF.

Curr Opin Nephrol Hypertens. 2006 Nov;15(6):643-7. Review.

PMID:
17053481
10.

Filtration function in glomerulonephritis.

Badr KF.

Kidney Int. 2005 Oct;68(4):1905-19. No abstract available.

11.

Isoprostanes and the kidney.

Badr KF, Abi-Antoun TE.

Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):236-43. Review.

PMID:
15650411
12.

Cytokine imbalance in acute coronary syndrome.

Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF.

Curr Opin Pharmacol. 2004 Apr;4(2):166-70. Review.

PMID:
15063361
13.

Molecular pharmacology of isoprostanes in vascular smooth muscle.

Habib A, Badr KF.

Chem Phys Lipids. 2004 Mar;128(1-2):69-73. Review.

PMID:
15037153
14.

Increased 5-lipoxygenase activating protein in immune-mediated experimental nephritis.

Montero A, Uda S, Kelavkar U, Yoshimura A, Badr KF, Munger KA.

J Nephrol. 2003 Sep-Oct;16(5):682-90.

PMID:
14733414
15.

Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.

Valdivielso JM, Montero A, Munger KA, Badr KF.

Adv Exp Med Biol. 2002;507:79-83. No abstract available.

PMID:
12664568
16.

Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.

Valdivielso JM, Montero A, Badr KF, Munger KA.

J Nephrol. 2003 Jan-Feb;16(1):85-94.

PMID:
12649539
17.

Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis.

Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF.

Carcinogenesis. 2001 Nov;22(11):1765-73.

PMID:
11698337
19.

F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes.

Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, Ziyadeh FN, Badr KF.

Kidney Int. 2000 Nov;58(5):1963-72.

20.

Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.

Kelavkar UP, Cohen C, Kamitani H, Eling TE, Badr KF.

Carcinogenesis. 2000 Oct;21(10):1777-87.

PMID:
11023533
22.

LTA4 hydrolase expression during glomerular inflammation: correlation of immunohistochemical localization with cytokine regulation.

Montero A, Uda S, Munger KA, Badr KF.

Adv Exp Med Biol. 1999;469:449-54. No abstract available.

PMID:
10667367
23.

15-Lipoxygenase in glomerular inflammation.

Montero A, Badr KF.

Exp Nephrol. 2000 Jan-Feb;8(1):14-9. Review.

PMID:
10644878
24.

Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis.

Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr KF.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13375-80.

25.

Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells.

Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A.

Kidney Int. 1999 Aug;56(2):471-8.

26.
27.

Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock.

Khan RZ, Badr KF.

Nephrol Dial Transplant. 1999 Apr;14(4):814-8. Review. No abstract available.

PMID:
10328448
28.

Arachidonic acid in cellular activation.

Badr KF.

Kidney Int. 1999 May;55(5):2070-1. No abstract available.

30.

Novel approaches to treatment of glomerulonephritis.

Nassar GM, Badr KF.

J Nephrol. 1998 Jul-Aug;11(4):177-84. Review.

PMID:
9702868
31.

Expression of recombinant rat interleukin-13 (IL-13) and generation of a neutralizing rat IL-13 antiserum.

Lakkis FG, Cruet EN, Nassar GM, Badr KF, Pascual DW.

Biochem Biophys Res Commun. 1997 Jun 27;235(3):529-32.

PMID:
9207190
32.
33.

Evidence for the distinct nature of F2-isoprostane receptors from those of thromboxane A2.

Fukunaga M, Yura T, Grygorczyk R, Badr KF.

Am J Physiol. 1997 Apr;272(4 Pt 2):F477-83.

PMID:
9140048
34.

Glomerulonephritis: roles for lipoxygenase pathways in pathophysiology and therapy.

Badr KF.

Curr Opin Nephrol Hypertens. 1997 Mar;6(2):111-8. Review. No abstract available.

PMID:
9146971
35.

Regulation of MAP-kinase activation by 8-iso-prostaglandin F2a in cultured rat aortic smooth muscle cells.

Fukunaga M, Yura T, Takahashi K, Badr KF.

Adv Exp Med Biol. 1997;433:193-6. No abstract available.

PMID:
9561133
36.

Mechanism of induction of prostaglandin E2 production by endothelin 1 in cultured rat mesangial cells.

Fukunaga M, Fujiwara Y, Ochi S, Yokoyama K, Shoji T, Fukuhara Y, Orita Y, Kamada T, Badr KF, Ueda N.

Exp Nephrol. 1996 Nov-Dec;4(6):340-9.

PMID:
9001889
37.

Alleviation of cisplatin nephrotoxicity: efficacy of local intra-arterial injection concomitant with hemodialysis.

Yura T, Badr KF, Yuasa S, Kurose T, Ohkawa M, Hando T, Fukunaga M, Matsuo H.

Blood Purif. 1996;14(2):146-56.

PMID:
8785030
38.

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury.

Badr KF.

Contrib Nephrol. 1996;118:113-25. Review. No abstract available.

PMID:
8744048
39.

Tachyphylaxis of human forearm vascular responses does not occur rapidly after exposure to isoproterenol.

Stein CM, Nelson R, Deegan R, He H, Inagami T, Frazer M, Badr KF, Wood M, Wood AJ.

Hypertension. 1995 Jun;25(6):1294-300.

PMID:
7768576
40.

Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release.

Fukunaga M, Yura T, Badr KF.

J Cardiovasc Pharmacol. 1995;26 Suppl 3:S51-2.

PMID:
8587462
41.
42.

Molecular and functional evidence for the distinct nature of F2-isoprostane receptors from those of thromboxane A2.

Yura T, Fukunaga M, Grygorczyk R, Makita N, Takahashi K, Badr KF.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:237-9. No abstract available.

PMID:
7732843
43.

Leukotrienes and 15-lipoxygenase products in glomerulonephritis.

Badr KF.

Adv Nephrol Necker Hosp. 1995;24:19-31. Review.

PMID:
7572409
44.

Role of leukotrienes and lipoxygenases in glomerular injury.

Nassar GM, Badr KF.

Miner Electrolyte Metab. 1995;21(4-5):262-70. Review.

PMID:
7565475
45.

Lipoxygenase products in normal and diseased glomeruli.

Badr KF, Lakkis FG.

Ann N Y Acad Sci. 1994 Nov 15;744:216-28. Review.

PMID:
7825843
46.

Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes.

Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF.

J Biol Chem. 1994 Nov 4;269(44):27631-4.

47.

Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase.

Akai Y, Homma T, Burns KD, Yasuda T, Badr KF, Harris RC.

Am J Physiol. 1994 Aug;267(2 Pt 1):C482-90.

PMID:
8074183
48.
49.

Consequences of acute nitric oxide synthesis inhibition in experimental glomerulonephritis.

Ferrario R, Takahashi K, Fogo A, Badr KF, Munger KA.

J Am Soc Nephrol. 1994 May;4(11):1847-54.

50.

Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy.

Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF.

J Am Soc Nephrol. 1994 Mar;4(9):1690-4.

Supplemental Content

Support Center